Phase 3-results for MOB-015 published in JAAD
STOCKHOLM, June 10[th] 2021. Moberg Pharma AB (OMX: MOB) announces that the results from the North American phase 3-study with MOB-015 (topical terbinafine) for the treatment of onychomycosis have been published in the Journal of the American Academy of Dermatology.In December 2019, Moberg Pharma announced positive top-line results from a phase 3-study including 365 patients, where the primary efficacy endpoint and the two key secondary efficacy endpoints were met. Mycological cure was achieved in 70 percent of patients receiving MOB-015 and complete cure was achieved in 4.5 percent of